Acticor Biotech Email Format

Biotechnology ResearchÎle-de-france, France2-10 Employees

Acticor Biotech is a biotechnology research company based in Paris, France, established as a spin-off from Inserm to pursue an innovative therapeutic approach for emergency treatment of ischemic strokes. Its work centers on developing glenzocimab, a drug aimed at addressing cardiovascular emergencies, with a focus on stroke, which remains a major cause of death and disability worldwide. The company seeks to fill a critical gap in stroke therapy by offering an option that could treat a broader portion of ischemic stroke patients beyond the current standard treatment. Acticor Biotech operates within the biotechnology research sector, leveraging academic origins and supported by notable French institutions; the firm is associated with ongoing clinical development and exploration of its approach in collaboration and research contexts. The organization is based in the Paris region, reflecting its roots in French biomedical research and its progression from academic work to clinical-stage development.

Sign up for free to view info

Company overview Employee directory